A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

Summary

This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.

Timeline

Start

2026-05

Primary completion

2028-04

Completion

2028-05

Drugs

Indications